About 30 results found for searched term "Gli" (0.016 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1799 | Imatinib Mesylate | Src-bcr-Abl |
| Gleevec, Glivec, CGP-57148B, STI-571 | ||
| Imatinib Mesylate is a Bcr-Abl tyrosine kinase inhibitor, with IC50 values of 2.9 and 3.9 μM for the inhibition of T-cell proliferation stimulated by PHA and DCs respectively. | ||
| M1894 | Rosiglitazone | PPAR |
| BRL 49653 | ||
| Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50=60 nM, Kd=40 nM). Rosiglitazone is an TRPC5 activator (EC50=30 μM) and TRPM3 inhibitor. | ||
| M1937 | Dapagliflozin | SGLT |
| BMS-512148 | ||
| Dapagliflozin (BMS-512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). | ||
| M1967 | Sitagliptin phosphate monohydrate | Dipeptidyl Peptidase |
| MK-0431, Januvia | ||
| Sitagliptin phosphate (MK-0431) is a potent inhibitor of dipeptidyl peptidase-4 (DPP-4) with IC50 of 19 nM. | ||
| M2002 | Canagliflozin | SGLT |
| JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284 | ||
| Canagliflozin is a potent, selective sodium glucose co-transporter 2 inhibitor. | ||
| M2038 | Rosiglitazone maleate | PPAR |
| Avandia | ||
| Rosiglitazone maleate (Avandia) is a potent and selective PPARγ ligand that binds to the PPARγ ligand-binding domain with a Kd value of 43 nM. | ||
| M2054 | Fasiglifam (TAK-875) Hemihydrate | GPR/FFAR |
| Fasiglifam Hemihydrate; TAK875 hydrate | ||
| Fasiglifam (TAK-875) Hemihydrate is a novel, orally available, selective GPR40 agonist. | ||
| M2341 | Trelagliptin | Dipeptidyl Peptidase |
| SYR-472 | ||
| Trelagliptin (SYR-472) is a novel once-weekly oral DPP-4 inhibitor for type 2 diabetes. | ||
| M2374 | Alogliptin | Dipeptidyl Peptidase |
| SYR-322 | ||
| Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. | ||
| M2667 | Empagliflozin | SGLT |
| BI 10773 | ||
| Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. | ||
| M2724 | Gliquidone | Potassium Channel |
| Glurenorm | ||
| Gliquidone is an ATP-sensitive K+ channel antagonist with IC50 of 27.2 nM. | ||
| M2814 | Linagliptin | Dipeptidyl Peptidase |
| BI-1356 | ||
| Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. | ||
| M3119 | Vildagliptin | Dipeptidyl Peptidase |
| LAF237; NVP-LAF 237 | ||
| Vildagliptin (LAF-237) inhibits DPP−4 with IC50 of 2.3 nM. | ||
| M3122 | Voglibose | Glucosidase |
| Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia. | ||
| M3283 | Pioglitazone | PPAR |
| U 72107 | ||
| Pioglitazone (U 72107) is a selective peroxisome proliferator-activated receptor gamma stimulator. | ||
| M3399 | Gliclazide | Potassium Channel |
| S1702; SE1702 | ||
| Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. | ||
| M3415 | Nateglinide | Potassium Channel |
| A-4166 | ||
| Nateglinide is an orally active, short-acting insulin-releasing compound that is also an inhibitor of DPP IV. Nateglinide inhibits ATP-sensitive K+ channels in islet β cells. Nateglinide is available for the study of type 2 diabetes mellitus (non-insulin-dependent). | ||
| M3435 | Saxagliptin | Dipeptidyl Peptidase |
| BMS-477118 | ||
| Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active inhibitor of dipeptidyl peptidase 4 (DPP-4) (Ki = 0.6-1.3 nM). Saxagliptin can be used in type 2 diabetes studies. | ||
| M3505 | Glipizide | Potassium Channel |
| CP 28720; K 4024 | ||
| Glipizide is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes. | ||
| M3547 | Glibenclamide | Others |
| Glyburide; RP-1127; BIIB093 | ||
| Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR). | ||
| M3562 | LY2608204 | Glucokinase (GK) |
| Globalagliatin | ||
| LY2608204 activates glucokinase (GK) with EC50 of 42 nM. | ||
| M3714 | Repaglinide | Potassium Channel |
| AG-EE, 623ZW | ||
| Repaglinide is an insulin secretagogue used in type 2 diabetes. | ||
| M3957 | Mitiglinide calcium | Potassium Channel |
| KAD-1229,S21403 | ||
| Mitiglinide (KAD 1229, S 21403), a derivative of benzysuccinic acid, is a potassium channel antagonist developed with Kissei for the study of type 2 diabetes. | ||
| M4936 | Omarigliptin | Dipeptidyl Peptidase |
| MK-3102 | ||
| Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor with IC50 of 1.6 nM; highly selective over all proteases tested (IC50 > 67 _mu_M). | ||
| M4968 | Mitiglinide calcium hydrate | Potassium Channel |
| KAD-1229 calcium hydrate; S-21403 calcium hydrate | ||
| Miglinide calcium hydrate is a compound used to study type 2 diabetes mellitus. It is a highly selective KATP channel antagonist. | ||
| M5150 | Glimepiride | PPAR |
| Glimperide; HOE-490; Amaryl | ||
| Glimepiride (Glimperide; HOE-490) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg. | ||
| M2407 | Atglistatin | Others |
| Atglistatin is a highly potent, and selective inhibitor of adipose triglyceride lipase (ATGL) with IC50 of 0.7 μM, high selectivity over other key metabolic lipases. | ||
| M5171 | Troglitazone (CS-045) | PPAR |
| Rezulin, Romglizone, Prelay, CS-045, CS045, CS 045, Romozin | ||
| Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-(PPAR) that is a ligand activated transcription factor regulating cell differentiation and growth. | ||
| M5249 | LX-4211 | SGLT |
| Sotagliflozin; LP-802034 | ||
| LX-4211 is an orally active, first-in-class dual SGLT1/2 inhibitor with IC50s of 36 nM and 1.8 nM, respectively, and is used in studies related to type 1 diabetes and heart failure. | ||
| M5254 | Ipragliflozin | SGLT |
| ASP 1941 | ||
| Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
